Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: In this study, we tested whether mutations in the methylation pathway genes ten-eleven-translocation 2 (TET2) and DNA methyltransferase gene 3A (DNMT3A) improve the responses of patients with myelodysplastic syndrome (MDS) to decitabine. Methods: We retrospectively sequenced the TET2 and DNMT3A genes from 70 patients diagnosed with de novo MDS between June 2008 and December 2011 and treated with a 5-day regimen of decitabine (290 cycles). We then analyzed treatment outcomes. Results: Patients with hematological improvement survived longer than those without hematological improvement (22.9 months vs. 10.9 months, p = 0.006). Among the 70 patients, 12 (17.1%) carried TET2 or DNMT3A mutations. The baseline characteristics of patients with wild type or mutated genes were similar. Patients with mutations in TET2 or DNMT3A had a higher overall response rate than those with the wild type genes (82.3% vs. 46.6%, p = 0.023). Multivariate analysis demonstrated that the TET2 or DMNT3A mutation status was associated with improved treatment responses and better overall survival among patients receiving decitabine. Conclusions: These results demonstrate that TET2 mutations enhance the treatment response of MDS patients to hypomethylating agents like decitabine.
Abstract
Background/Aims: In this study, we tested whether mutations in the methylation pathway genes ten-eleven-translocation 2 (TET2) and DNA methyltransferase gene 3A (DNMT3A) improve the responses of patients with myelodysplastic syndrome (MDS) to decitabine. Methods: We retrospectively sequenced the TET2 and DNMT3A genes from 70 patients diagnosed with de novo MDS between June 2008 and December 2011 and treated with a 5-day regimen of decitabine (290 cycles). We then analyzed treatment outcomes. Results: Patients with hematological improvement survived longer than those without hematological improvement (22.9 months vs. 10.9 months, p = 0.006). Among the 70 patients, 12 (17.1%) carried TET2 or DNMT3A mutations. The baseline characteristics of patients with wild type or mutated genes were similar. Patients with mutations in TET2 or DNMT3A had a higher overall response rate than those with the wild type genes (82.3% vs. 46.6%, p = 0.023). Multivariate analysis demonstrated that the TET2 or DMNT3A mutation status was associated with improved treatment responses and better overall survival among patients receiving decitabine. Conclusions: These results demonstrate that TET2 mutations enhance the treatment response of MDS patients to hypomethylating agents like decitabine.
참고문헌 (30)
- Greenberg P, "International scoring system for evaluating prognosis in myelodysplastic syndromes", Blood, 89, pp.2079~2088 (1997)
- Greenberg PL, "Revised international prognostic scoring system for myelodysplastic syndromes", Blood, 120, pp.2454~2465 (2012)
- Tefferi A, "Classification and diagnosis of myeloproliferative neoplasms : the 2008 World Health Organization criteria and point-of-care diagnostic algorithms", Leukemia, 22, pp.14~22 (2008)
- Sekeres MA, "How we treat higher-risk myelodysplastic syndromes", Blood, 123, pp.829~836 (2014)
- Silverman LR, "Further analysis of trials with azacitidine in patients with myelodysplastic syndrome : studies 8421, 8921, and 9221by the Cancer and Leukemia Group B", J Clin Oncol, 24, pp.3895~3903 (2006)
- Silverman LR, "Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome : a study of the cancer and leukemia group B", J Clin Oncol, 20, pp.2429~2440 (2002)
- Fenaux P, "Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study", Lancet Oncol, 10, pp.223~232 (2009)
- Itzykson R, "Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine", Blood, 117, pp.403~411 (2011)
- Kantarjian H, "Decitabine improves patient outcomes in myelodysplastic syndromes : results of a phase III randomized study", Cancer, 106, pp.1794~1803 (2006)
- Kantarjian H, "Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia", Blood, 109, pp.52~57 (2007)
- Lee JH, "A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome", Haematologica, 96, pp.1441~1447 (2011)
- Moon JH, "Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment", Ann Hematol, 89, pp.681~689 (2010)
- Bejar R, "The genetic basis of myelodysplastic syndromes", Hematol Oncol Clin North Am, 24, pp.295~315 (2010)
- Walter MJ, "Recurrent DNMT3A mutations in patients with myelodysplastic syndromes", Leukemia, 25, pp.1153~1158 (2011)
- Papaemmanuil E, "Clinical and biological implications of driver mutations in myelodysplastic syndromes", Blood, 122, pp.3616~3627 (2013)
- Lin J, "IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome", Ann Hematol, 91, pp.519~525 (2012)
- Traina F, "Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms", Leukemia, 28, pp.78~87 (2014)
- Cazzola M, "The genetic basis of myelodysplasia and its clinical relevance", Blood, 122, pp.4021~4034 (2013)
- Scopim-Ribeiro R, "Ten-eleven-translocation 2(TET2)is downregulated in myelodysplastic syndromes", Eur J Haematol, 94, pp.413~418 (2015)
- Haferlach T, "Landscape of genetic lesions in 944 patients with myelodysplastic syndromes", Leukemia, 28, pp.241~247 (2014)
- Itzykson R, "Impact of TET2mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias", Leukemia, 25, pp.1147~1152 (2011)
- Cheson BD, "Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia", J Clin Oncol, 21, pp.4642~4649 (2003)
- Prebet T, "Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. Version 2", J Clin Oncol, 29, pp.3322~3327 (2011)
- Jabbour E, "Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy", Cancer, 116, pp.3830~3834 (2010)
- Bejar R, "Clinical effect of point mutations in myelodysplastic syndromes", N Engl J Med, 364, pp.2496~2506 (2011)
- Bejar R, "Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes", J Clin Oncol, 30, pp.3376~3382 (2012)
- Kosmider O, "TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia", Haematologica, 94, pp.1676~1681 (2009)
- Zhang L, "The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes", Leuk Res, 39, pp.6~17 (2015)
- Ades L, "Myelodysplastic syndromes", Lancet, 383, pp.2239~2252 (2014)
- Bravo GM, "Integrating genetics and epigenetics in myelodysplastic syndromes : advances in pathogenesis and disease evolution", Br J Haematol, 166, pp.646~659 (2014)